As survival rates for cystic fibrosis have improved dramatically over the past several decades, a new set of comorbidities has emerged to challenge patients and clinicians alike. Cystic fibrosis-related diabetes (CFRD) is now one of the most common and clinically significant complications, affecting approximately 20% of adolescents and up to 50% of adults with CF. Unlike classic type 1 or type 2 diabetes, CFRD has a distinct pathophysiology driven by progressive pancreatic damage, chronic inflammation, and insulin resistance from recurrent infections and corticosteroid use. The interplay between exocrine pancreatic insufficiency, insulin secretion defects, and peripheral insulin resistance creates a unique metabolic state that demands specialized management approaches. Recognizing CFRD as a distinct entity, rather than forcing it into existing diabetes classification frameworks, is the first step toward effective care.

The diagnosis of CFRD carries serious implications. It is associated with more rapid decline in lung function, worse nutritional status, and a fivefold increase in mortality compared to patients with CF without diabetes. Yet because CFRD often develops insidiously, with few classic symptoms, it can go undetected for years without systematic screening. Annual oral glucose tolerance testing is recommended starting at age 10 in all CF patients, but adherence to screening guidelines remains variable across care centers. This is where a structured, multidisciplinary team becomes not just helpful but essential. Early detection combined with coordinated management has been shown to blunt the negative impact of CFRD on pulmonary function and nutritional status, making systematic screening and rapid response to abnormal results a core priority for any CF care program.

The Unique Pathophysiology of CFRD

Pancreatic Destruction and Insulin Deficiency

The basic defect in cystic fibrosis involves a mutation in the CFTR gene, which impairs chloride transport across epithelial surfaces. In the pancreas, thickened secretions block the ducts, leading to progressive destruction of both exocrine and endocrine tissues. Over time, the islets of Langerhans become scarred and lose beta cells that produce insulin, as well as alpha cells that produce glucagon. The result is a relative insulin deficiency that worsens with age. Unlike type 1 diabetes, however, the loss of insulin secretion in CFRD is gradual, and some endogenous insulin production often persists well into adulthood. This partial preservation of beta-cell function means that diabetic ketoacidosis is rare in CFRD, though it can occur during severe illness. The gradual nature of insulin decline also means that glucose abnormalities may be intermittent at first, appearing only during periods of stress or infection before becoming persistent.

Insulin Resistance and the Role of Inflammation

Superimposed on this insulin deficiency is a component of insulin resistance driven by several factors that interact in complex ways. Recurrent pulmonary infections cause systemic inflammation, which increases cytokines like TNF-alpha and interleukins that interfere with insulin signaling at the cellular level. This infection-driven insulin resistance can be dramatic, with insulin requirements sometimes doubling or tripling during a pulmonary exacerbation. Chronic use of corticosteroids, both inhaled and systemic, further worsens insulin sensitivity by promoting gluconeogenesis and impairing peripheral glucose uptake. Liver disease associated with CF can contribute to hepatic insulin resistance, while poor nutritional status and malnutrition paradoxically also impair glucose metabolism through mechanisms involving reduced muscle mass and altered adipokine profiles. This combination means that CFRD management cannot rely solely on insulin dosing adjustments; it must address the underlying inflammatory state, infection control, and nutritional optimization simultaneously. No single specialist can tackle all these domains, which is why multidisciplinary teams have become the standard of care.

The Glucose-Cystic Fibrosis Vicious Cycle

A particularly challenging aspect of CFRD pathophysiology is the bidirectional relationship between hyperglycemia and CF lung disease. High blood glucose levels impair neutrophil function, reduce mucociliary clearance, and create a favorable environment for bacterial growth, particularly Pseudomonas aeruginosa and Staphylococcus aureus. This leads to more frequent and severe pulmonary infections, which in turn increase systemic inflammation and insulin resistance, worsening hyperglycemia. Breaking this cycle requires simultaneous attention to both glucose control and lung health, a task that demands close collaboration between endocrinology and pulmonology specialists.

Core Members of the Multidisciplinary Team

A well-functioning multidisciplinary team for CFRD typically includes at least eight distinct professional roles, though in practice some functions may be combined or shared depending on center resources. The key is that each member brings a specific expertise and that all members communicate regularly to coordinate the patient's care plan. Regular team huddles, shared electronic health record documentation, and structured care pathways help ensure that no aspect of the patient's complex needs is overlooked.

Endocrinologist

The endocrinologist takes primary responsibility for diagnosing CFRD, initiating and adjusting insulin therapy, and managing other aspects of glucose metabolism. Unlike type 1 diabetes where basal-bolus insulin regimens are standard, CFRD often requires a more nuanced approach. Many patients benefit from insulin analogs with a shorter duration of action or even prandial-only insulin regimens because of the variable absorption and unpredictable eating patterns common in CF. Some patients may require only a single daily dose of long-acting insulin when their disease is mild, while others need complex multiple-injection regimens during exacerbations. The endocrinologist must also monitor for microvascular complications, which are rare but possible with long-standing CFRD, and manage any additional endocrine issues such as hypogonadism, low bone density, or thyroid dysfunction. An endocrinologist experienced in CFRD recognizes that traditional HbA1c targets need adjustment, as HbA1c can be falsely low due to reduced red blood cell lifespan from chronic inflammation and hemolysis.

Pulmonologist

Lung health is the strongest predictor of survival in cystic fibrosis, and it is intimately connected to glucose control. Hyperglycemia impairs neutrophil function, increases airway inflammation, and promotes bacterial growth in the lungs. A multidisciplinary team ensures that the pulmonologist is aware of the patient's glycemic status when making decisions about antibiotic therapy, airway clearance, and anti-inflammatory treatments. Conversely, when a patient experiences an acute pulmonary exacerbation, insulin requirements can increase dramatically, and the team must be ready to adjust the diabetes management plan accordingly. The pulmonologist also plays a role in identifying patients who may be developing CFRD, as declining lung function or frequent exacerbations can be early warning signs of glucose intolerance.

Registered Dietitian

Nutrition is the cornerstone of CF care, and CFRD adds an extra layer of complexity. Patients with CF typically require a high-calorie, high-fat diet to maintain body weight, but traditional diabetes dietary advice focuses on carbohydrate counting and limiting simple sugars. The dietitian on the team must reconcile these conflicting goals by creating nutrition plans that provide adequate energy for lung function and growth while stabilizing blood glucose levels. This often involves using carbohydrate counting with flexible insulin dosing, recommending high-protein snacks that have minimal impact on blood glucose, and ensuring adequate pancreatic enzyme replacement therapy to optimize nutrient absorption. The dietitian also monitors weight trends, addresses feeding difficulties, and provides guidance on managing meals during illness when appetite is poor but insulin requirements are high. Timing of nutrition interventions around pulmonary therapies and exercise is another area where the dietitian's expertise is indispensable.

Diabetes Nurse Educator and CF Nurse Specialist

Nurses are crucial in delivering hands-on education and practical support. The diabetes nurse educator teaches patients and families how to perform blood glucose monitoring, use insulin pens or pumps, recognize and treat hypoglycemia, and adjust doses for meals and illness. The CF nurse specialist coordinates care, manages phone calls and follow-ups, and helps patients navigate the complexities of multiple daily therapies. In many centers, a single advanced practice nurse may serve both roles, which has the advantage of providing a consistent point of contact for the patient. These nurses are often the first to hear about emerging problems, such as nausea that could signal gastroparesis or changes in appetite that might require insulin adjustment, making them a vital link between patients and the rest of the team.

Mental Health Professional

The psychological burden of living with two chronic, progressive diseases is enormous. Depression and anxiety are highly prevalent among individuals with CF, and the added demands of diabetes self-management can exacerbate these conditions. A psychologist, psychiatrist, or licensed clinical social worker integrated into the team can provide cognitive-behavioral therapy, stress management techniques, and medication if needed. Addressing mental health not only improves quality of life but also enhances adherence to treatment regimens and improves clinical outcomes. The mental health professional also helps patients cope with the fear of hypoglycemia, which can be a major barrier to achieving good glycemic control, and addresses diabetes-related distress that may lead to treatment burnout.

Physical Therapist or Exercise Specialist

Exercise is beneficial for both pulmonary function and insulin sensitivity. However, patients with CF and CFRD may have unique challenges such as limited exercise tolerance, fear of hypoglycemia during activity, or electrolyte imbalances. A physical therapist can design safe, individualized exercise plans that take into account lung status, nutritional needs, and glucose monitoring requirements. The physical therapist works closely with the dietitian and endocrinologist to ensure that exercise is properly timed with meals and insulin doses to prevent hypoglycemia. For patients with advanced lung disease, the physical therapist can recommend modified activities that provide cardiovascular benefits without exceeding the patient's respiratory capacity.

Social Worker and Care Coordinator

Navigating healthcare systems, insurance coverage, and financial assistance for insulin, continuous glucose monitors, and other supplies can be overwhelming. A social worker helps patients access resources, coordinate school or work accommodations, and plan for transitions such as moving from pediatric to adult care. The social worker also addresses social determinants of health, such as food insecurity or unstable housing, that can profoundly impact diabetes management. For young adults transitioning to independence, the social worker provides guidance on insurance options, disability benefits, and vocational support.

Clinical Pharmacist

Given the polypharmacy involved in CF care, a pharmacist with expertise in drug interactions and medication management can optimize therapy. They can identify potential interactions between insulin and antibiotics, ensure proper storage of medications, and help patients manage their long list of daily treatments. The pharmacist also provides education on proper insulin injection technique, reviews medication reconciliation at each visit, and helps streamline regimens to reduce pill burden when possible.

Integrated Care Models for CFRD

Combined CF-Endocrine Clinics

Many leading CF centers have adopted a model where the patient sees the pulmonologist, endocrinologist, dietitian, and nurse educator all in the same visit. This one-stop shop approach reduces travel burden, improves communication among providers, and allows for real-time adjustments to treatment plans. For example, if the pulmonologist decides to start a course of oral corticosteroids for a pulmonary exacerbation, the endocrinologist can immediately increase the insulin dose and provide teaching to the patient. These combined clinics have been shown to improve adherence to screening guidelines, reduce time to insulin initiation, and improve glycemic outcomes. They also provide a natural forum for case discussions among team members, fostering a shared mental model of each patient's status and goals.

Telehealth and Remote Monitoring

With the expansion of telehealth, many CF centers now offer virtual multidisciplinary visits. Continuous glucose monitors (CGMs) provide real-time data that can be reviewed remotely by the diabetes team, reducing the need for frequent in-person visits. Telehealth also allows patients living far from specialized CF centers to access expert care without traveling long distances. Studies indicate that telehealth-based multidisciplinary care achieves comparable outcomes to in-person care for stable patients while improving convenience and satisfaction. The combination of CGM data sharing and video visits enables proactive insulin adjustments and early intervention for emerging problems, such as a rising glucose trend that may herald the onset of an infection.

Standardized Care Pathways and Protocols

To ensure consistency and quality across the multidisciplinary team, many centers have developed standardized care pathways for CFRD. These protocols outline screening schedules, diagnostic criteria, insulin initiation algorithms, and follow-up intervals. They also define when consultations with subspecialists, such as gastroenterology for gastroparesis or nephrology for microalbuminuria, should be triggered. Standardized pathways reduce variability in care and ensure that all team members are working from the same evidence base, even when individual team members may change over time.

Measurable Benefits of a Multidisciplinary Approach

The evidence supporting multidisciplinary team-based care for chronic diseases is robust, and CFRD is no exception. Research from the Cystic Fibrosis Foundation Patient Registry has shown that patients cared for at centers with dedicated CFRD clinics have better glycemic control, slower decline in lung function, and lower rates of severe hypoglycemia compared to those receiving fragmented care. Other documented benefits include earlier detection of comorbidities such as CF-related liver disease, bone disease, and depression; improved nutritional outcomes with higher BMI percentiles and better fat-soluble vitamin levels; reduced hospitalizations for both pulmonary exacerbations and diabetic ketoacidosis; enhanced patient and family satisfaction due to consistent, coordinated messaging that reduces confusion and conflicting advice; and lower overall healthcare costs due to fewer emergency visits and better preventive care that minimizes expensive acute interventions.

Overcoming Challenges in Building and Sustaining the Team

Despite the clear benefits, implementing a truly integrated multidisciplinary team is not without obstacles. Funding is a major barrier: many CF centers operate under tight budgets, and adding dedicated endocrinology or mental health professionals requires institutional commitment. Advocacy from patient organizations and professional societies can help make the case for investment by demonstrating the return on investment through reduced hospitalizations and improved outcomes. Communication among team members can be hampered by separate electronic health record systems, scheduling difficulties, and varying professional cultures. Regular team meetings and shared documentation tools help bridge these gaps. In smaller centers, one person may be forced to wear multiple hats, diluting their expertise, but even a partially integrated team with strong communication can achieve meaningful improvements compared to completely siloed care. Additionally, lack of standardized training for CFRD management means that not all specialists are equally familiar with the nuances of the disease. Continuing education programs and online resources, such as those provided by the Cystic Fibrosis Foundation, help ensure that all team members stay current with best practices. Overcoming these challenges requires strong leadership, institutional prioritization of team-based care, and advocacy from patient organizations that have published guidelines emphasizing the importance of multidisciplinary teams.

Future Directions and Emerging Opportunities

As understanding of CFRD continues to evolve, new therapeutic targets and care models are emerging that will further benefit from multidisciplinary collaboration. CFTR modulator therapies have already been shown to improve insulin secretion in some patients, with studies documenting increased endogenous insulin production and improved glucose tolerance after initiation of highly effective modulator therapy. Ongoing research is investigating whether early initiation of modulators can prevent or delay the onset of CFRD altogether, which would represent a paradigm shift in how the condition is approached. Insulin sensitizers such as metformin have shown mixed results in CFRD but may still have a role in well-selected patients when used under careful supervision. Personalized medicine approaches based on genetic mutations, microbiome analysis, and metabolomics could soon allow teams to tailor diabetes management even more precisely to each patient's unique pathophysiology. The integration of artificial intelligence into CGM data analysis is another promising frontier, with machine learning algorithms being developed to predict glucose excursions before they occur, alerting the team to intervene proactively. Closed-loop insulin delivery systems, or artificial pancreas technology, are being studied in CFRD and may eventually reduce the burden of self-management while improving glycemic outcomes.

Research from the National Heart, Lung, and Blood Institute and other funding bodies continues to explore the complex metabolic interactions in CF. Large multicenter trials are needed to determine optimal insulin regimens, the role of non-insulin therapies such as GLP-1 receptor agonists or SGLT2 inhibitors, and the best models for delivering multidisciplinary care across different healthcare settings. The emergence of patient-reported outcome measures and digital health tools will also help teams better capture the impact of their interventions on quality of life and daily functioning.

Building Your Center's Multidisciplinary Team

For centers looking to establish or strengthen a multidisciplinary CFRD program, a practical stepwise approach is recommended. Start by designating a team lead, often an endocrinologist or pulmonary specialist with a specific interest in CFRD, who can champion the initiative. Conduct a needs assessment to identify the most critical gaps in current care, whether that is access to dietitian support, mental health services, or nursing education. Leverage existing relationships with hospital administration to make the case for dedicated clinic time and resources. Establish clear communication pathways, such as a shared electronic health record template or a regular multidisciplinary case conference. Finally, track outcomes from the start, measuring metrics such as screening completion rates, time from diagnosis to insulin initiation, HbA1c trends, lung function trajectories, and patient satisfaction. Demonstrating improvements in these outcomes builds the case for further investment and helps sustain momentum.

Conclusion

Cystic fibrosis-related diabetes is a challenging, multifaceted condition that cannot be managed effectively by any single provider acting alone. The synergy achieved through a multidisciplinary team, in which each member contributes their specialized knowledge while maintaining a unified care plan, offers the best chance for optimal outcomes. By addressing glycemic control, lung health, nutrition, mental well-being, and social support in a coordinated manner, these teams help patients with CF and CFRD live longer, healthier, and more fulfilling lives. For healthcare institutions caring for people with cystic fibrosis, investing in robust multidisciplinary teams is not merely an option; it is an imperative. The Cystic Fibrosis Foundation's Clinical Care Guidelines reinforce this standard, and the evidence continues to grow that collaboration saves lives.

Ultimately, managing CFRD is about more than just blood sugar numbers; it is about treating the whole person in the context of a complex, lifelong disease. Multidisciplinary teams embody that principle, and as medical knowledge advances, their role will only become more central. For patients, families, and clinicians alike, embracing the team approach is the most promising path forward in the fight against cystic fibrosis and its complications.